A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
59,84Â R$
0,00%
(0,00) 1K
16-okt, 16:56:00 (GMT-3) · BRL
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoA1LN34 tikeri uchun statistika yaratilmoqda...
Ochish
59,28Â R$
Yuqori
59,84Â R$
Past
59,28Â R$
Bozor kapitali
31,02Â mlrd
Oʻrtacha hajm
446,00
Hajmi
17,00
52 haftalik eng yuqori
131,80Â R$
52 haftalik eng past
50,25Â R$
Muomaladagi aksiyalar
133,81Â mln
Xodimlar soni
2Â ming
Ochish
59,28Â R$
Yuqori
59,84Â R$
Past
59,28Â R$
Bozor kapitali
31,02Â mlrd
Oʻrtacha hajm
446,00
Hajmi
17,00
52 haftalik eng yuqori
131,80Â R$
52 haftalik eng past
50,25Â R$
Muomaladagi aksiyalar
133,81Â mln
Xodimlar soni
2Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ad-hoc-news.de
·
3 soat oldin
BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals stock
ad-hoc-news.de
·
2 kun oldin
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Alnylam Pharmaceuticals Inc Bdr haqida